Page 9 - Small Pharma News Today

LISBON, Portugal, March 8, 2023 /PRNewswire/ -- Hovione, the leader in spray drying and particle...

-Patients’ self-reported depression and wellbeing scores corroborate MADRS efficacy data-Statistically significant improvement in anxiety symptoms offers...

In the Pulse, the monthly psychedelics industry roundup from <i>Technology Networks </i> and <i>Analytical Cannabis</i>, we highlight some of the most significant psychedelic industry news from the past month. This includes important announcements, pre-clinical work and the latest from groundbreaking psychedelic clinical trials.

Almac Group, the global contract development and manufacturing organisation, is delighted to announce it has won six CDMO Leadership Awards for 2023. The CDMO Leadership Awards recognise top performing CDMOs, celebrating outstanding companies in drug development and manufacturing, emphasising high standards of ...

First subject dosed with company’s SPL028 – a proprietary deuterated DMT candidate - News - PharmaTimes

This article by James Hallifax was originally published on Microdose and appears here with permission. 2022 was a milestone year for th...

Top-line phase 2a trial results of experimental psychedelic tryptamine showed a 57% reduction in major depressive disorder symptoms 3 months after a single dose when combined with supportive therapy.

DMT — the most potent psychedelic known to man — treats people with severe depression after a single dose, a cutting-edge clinical trial suggests. Up to six in ten who received a single dose of DMT intravenously before therapy were declared...

First placebo-controlled efficacy study completed to date exploring a short-duration psychedelic for depression demonstrates rapid and durable response Primary endpoint met with a statistically significant

Up to six in ten who received a single dose of DMT intravenously before therapy were declared depression-free three months later, in a clinical trial by Canada-based Small Pharma.